To obtain the subject new compound having adverse effect lower than that of a conventional prostaglandin(PG) E analogue, having strong anti- ulcer action excellent in persistency and having triple bond at 13 and 14 positions and having sulfonamide group at α chain end.
This compound is represented by formula I {A is a group represented by formula II (R4 is H, an alkyl or a halogen) or a group of the formula, (CH2)p [(p) is 0-3]; B is a group represented by formula III or the formula, (CH2)q [(q) is 1-4]; X is methylene or the like; R1 is an alkyl or the like; R2 is H or the like; R3 is an alkyl or the like; (n) and (m) are each 0 or 1}, e.g. (2E)-16-phenoxy-17,18,19,20-tetranor-2,3,13,14-tetrahydro-PGE1 methylsulfonylamide. The compound of formula I is obtained by reacting, e.g. a compound of formula IV with a compound of the formula, A-X-B-CONHSO2- R1 and a radical generator and a radical reducing agent and deprotecting the protected group of hydroxyl group of the resultant compound.
KAMEO KAZUYA
TANAMI TOORU
TANAKA HIDEO
SHIMAZAKI YOICHI
ONO NAOYA
SATO FUMIE